Wells Fargo’s AEON Biopharma AEON Stock Holding History

Wells Fargo’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65	Hold	90	–	–	﹤0.01%	6691
2026 Q1	$89	Hold	90	–	–	﹤0.01%	6516
2025 Q4	$99	Hold	90	–	–	﹤0.01%	6431
2025 Q3	$73	Hold	90	–	–	﹤0.01%	6425
2025 Q2	$68	Hold	90	–	–	﹤0.01%	6532
2025 Q1	$52	Hold	90	–	–	﹤0.01%	6449
2024 Q4	$3.51K	Buy	+90	New	+$5.24K	﹤0.01%	6118
2024 Q2	–	Sell	-2	Closed	-$1.61K	–	6874
2024 Q1	$1.61K	Hold	2	–	–	﹤0.01%	6067
2023 Q4	$986	Hold	2	–	–	﹤0.01%	6226
2023 Q3	$728	Buy	+2	New	+$916	﹤0.01%	6274
2022 Q1	–	Sell	-3,945	Closed	-$2.76M	–	6976
2021 Q4	$2.76M	Hold	3,945	–	–	﹤0.01%	3176
2021 Q3	$2.77M	Hold	3,945	–	–	﹤0.01%	3392
2021 Q2	$2.73M	Buy	+3,945	New	+$2.76M	﹤0.01%	3409

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's AEON Position: Q2 2026 in Review

Wells Fargo held its AEON Biopharma (AEON) position steady in Q2 2026 at 90 shares worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #6691.

Wells Fargo first reported a position in AEON in Q2 2021 and has held it in 13 quarters since. The position peaked at $2.77M in Q3 2021. 22 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

Wells Fargo held 90 shares of AEON Biopharma worth $65 as of Q2 2026.
Wells Fargo left its AEON Biopharma share count unchanged in Q2 2026.
AEON Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6691 holding.
Wells Fargo first reported a position in AEON Biopharma in Q2 2021 and has held it in 13 quarters since.
Wells Fargo's AEON Biopharma position peaked at $2.77M in Q3 2021.
22 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.